Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial
Figure 2
Fundus photographs showing pre-proliferative changes (a) at baseline in a patient who had a regression of eye lesions after three years of trandolapril therapy (b). This picture provides a comprehensive example of three typical lesions, microaneurysms (MA), hemorrages (E), and hard exudates (HE, that may regress in type 2 diabetic patients on ACE inhibitor therapy combined to intensified metabolic and blood pressure control, as in the BENEDICT trial.